Insight Molecular Diagnostics Inc. IMDX
We are a pioneering diagnostics technology company. Our mission is to expand access to novel molecular diagnostic testing, most immediately in the transplanted organ rejection testing category.
We are developing molecular diagnostic test kits designed to empower our customers to run their own tests in-house to participate in the patient-care value chain, which is counter-positioned with the send-out-testing central laboratory model. Our decentralized approach also puts testing in the hands of researchers to enable more studies, which we believe can improve standards of care while also creating demand for more testing. We believe that combining innovative science with a simple, but disruptive, business model can create substantial value. Our initial targeted customer institutions are hospitals, transplant centers and labs. The decisions to deploy our tests come from doctors, including surgeons, nephrologists and oncologists, as well as researchers, pathologists, lab directors, medical directors, department heads, lab managers and chief medical officers.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.1M | $1.9M | $1.5M | $958.0K | $2.2M | $1.2M | — | — | — | — |
| Cost of revenue | $1.8M | $1.1M | $1.0M | $880.0K | $697.0K | $1.9M | — | — | — | — |
| Gross profit | $2.3M | $740.0K | $413.0K | -$18.0K | $1.4M | -$639.0K | — | — | — | — |
| R&D | $15.9M | $9.8M | $9.3M | $7.3M | $5.0M | $9.8M | $6.8M | $6.5M | $7.2M | $5.7M |
| SG&A | $10.6M | $10.2M | $11.2M | $21.9M | $22.3M | $16.8M | $13.3M | $7.0M | $9.2M | $4.3M |
| Total operating expenses | $53.4M | $61.8M | $25.5M | $18.0M | $55.1M | $29.1M | $22.2M | $15.2M | $18.8M | $11.1M |
| Operating income | -$51.1M | -$61.0M | -$25.1M | -$18.0M | -$53.7M | -$29.7M | -$22.2M | -$15.2M | -$18.8M | -$11.1M |
| Interest expense | $109.0K | $84.0K | $52.0K | $83.0K | $209.0K | $252.0K | $299.0K | $216.0K | $217.0K | $0 |
| Pre-tax income | -$50.2K | -$60.7M | -$24.9M | -$18.6M | -$52.9M | -$31.2M | -$22.4M | — | — | — |
| Income tax | $0 | $0 | $0 | — | $9.3M | $1.3M | — | — | — | — |
| Net income | -$50.2K | -$60.7K | -$27.8K | -$72.9M | -$64.1M | -$29.9M | -$22.4M | -$15.8M | -$19.4M | -$11.2M |
| EPS, basic | -1.65 | -4.66 | -3.75 | -13.25 | -0.72 | — | — | — | — | — |
| EPS, diluted | -1.65 | -4.66 | -3.75 | -13.25 | -0.72 | -0.46 | -0.44 | -0.42 | -0.64 | -0.42 |
| Shares, diluted (wtd. avg.) | 30.5M | 13.1M | 7.7M | 5.5M | 88,920 | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $11.6M | $8.6M | $9.4M | $20.0M | $32.9M | $7.1M | $22.1M | $8.0M | $7.6M | $10.2M |
| Receivables | $1.1M | $1.6M | $484.0K | $2.0M | $1.4M | $203.0K | — | — | — | — |
| Inventory | $446.0K | $410.0K | — | — | — | — | — | — | — | — |
| Total current assets | $15.3M | $11.8M | $10.7M | $25.5M | $39.1M | $9.2M | $23.0M | $8.6M | $8.5M | $12.7M |
| Property, plant and equipment | $9.2M | $6.3M | $4.7M | $8.7M | $7.1M | $4.4M | $3.6M | $614.0K | $822.0K | $688.0K |
| Goodwill | — | — | — | — | $18.7M | $9.5M | $9.2M | — | — | — |
| Other intangibles | $0 | $14.6M | $56.6M | $61.6M | $61.7M | $15.0M | — | — | $746.0K | $988.0K |
| Total assets | $25.8M | $35.1M | $74.9M | $100.1M | $159.6M | $55.4M | $39.9M | $9.5M | $10.2M | $14.4M |
| Accounts payable | $2.5M | $1.6M | $953.0K | $1.3M | $1.8M | $432.0K | $469.0K | $166.0K | $175.0K | $422.0K |
| Total current liabilities | $12.1M | $7.3M | $7.2M | $12.1M | $14.1M | $9.0M | $4.4M | $5.6M | $4.5M | $4.3M |
| Long-term debt | — | — | — | — | — | — | — | — | $1.9M | — |
| Total liabilities | $57.2M | $47.4M | $49.3M | $60.5M | $94.3M | $21.9M | $9.0M | $6.1M | $5.8M | $4.6M |
| Retained earnings | -$400.8M | -$350.5M | -$289.9M | -$260.7M | -$187.8M | -$123.7M | -$93.7M | -$71.3M | -$54.7M | -$35.3M |
| Total equity | -$31.5M | -$12.3M | $20.5M | $34.3M | $65.2M | $33.5M | $30.8M | $3.4M | $4.4M | $9.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22.2M | -$20.7M | -$23.3M | -$45.6M | -$35.9M | -$26.0M | -$19.7M | -$11.6M | -$13.4M | -$7.5M |
| Depreciation and amortisation | $2.2M | $1.6M | $1.7M | $1.5M | $844.0K | $313.0K | $344.0K | $438.0K | $338.0K | $145.0K |
| Stock-based compensation | $2.2M | $1.8M | $2.8M | $10.0M | $6.8M | $5.1M | $3.0M | $1.5M | $1.6M | — |
| Capital expenditure | $3.2M | $516.0K | $281.0K | $4.3M | $2.2M | $1.2M | $918.0K | $31.0K | $91.0K | $106.0K |
| Investing cash flow | -$3.2M | -$512.0K | -$932.0K | -$4.3M | -$14.0M | -$11.7M | -$12.4M | -$31.0K | $843.0K | -$181.0K |
| Financing cash flow | $28.1M | $20.4M | $12.2M | $35.8M | $78.4M | $22.8M | $47.9M | $12.1M | $10.0M | $9.9M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-020502.
Plot the figures US dollars
- R&D
- Property, plant and equipment
- Total current liabilities
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $5.7M | $7.2M | $6.5M | $6.8M | $9.8M | $5.0M | $7.3M | $9.3M | $9.8M | $15.9M |
| Property, plant and equipment | $688.0K | $822.0K | $614.0K | $3.6M | $4.4M | $7.1M | $8.7M | $4.7M | $6.3M | $9.2M |
| Total current liabilities | $4.3M | $4.5M | $5.6M | $4.4M | $9.0M | $14.1M | $12.1M | $7.2M | $7.3M | $12.1M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Other event Item 8.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2835
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | $42.18B | 40.9x | 10.4% |
| LNTH | Lantheus Holdings, Inc. | $6.59B | 29.6x | 0.5% |
| CLDX | Celldex Therapeutics, Inc. | $3.12B | — | -78.0% |
| NEOG | NEOGEN CORP | $2.58B | — | -2.7% |
| NTLA | Intellia Therapeutics, Inc. | $1.79B | — | 16.9% |
| QDEL | QuidelOrtho Corp | $958.0M | — | -1.9% |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $873.6M | — | — |
| TKNO | Alpha Teknova, Inc. | $371.5M | — | 7.4% |